Glan Clwyd’s haematology and research teams have been awarded second place for their involvement in trials and studies around Acute Myeloid Leukaemia (AML) at a prestigious national awards ceremony.
The teams were named runner-up in the National AML Trial Team of The Year category at the annual Acute Myeloid Leukaemia Academy in Birmingham.
Their achievement was all the more impressive as it was the only district hospital collective to enter, alongside larger hospitals and centres of excellence.
More than 80 hospitals across the UK treat AML and the awarding panel remarked how Glan Clwyd stood out from all other applications.
The awarding panel praised Glan Clwyd’s high commitment to AML research, in a smaller centre with limited resources.
AML experts from across the UK meet up at the Academy to discuss the most up to date treatments and research.
The recognition came for the work at Glan Clwyd around National Cancer Research Institute AML trials, Trials Acceleration Programme (TAP) trials, patient recruitment and engagement with patient groups.
The judges also recognised the work done to interact with the local community to improve delivery of AML and haemato-oncology trials, along with industry sponsored research and involvement in future UK AML trial development.
There was also praise for being heavily involved in major AML studies across the UK whilst simultaneously working on other haemato-oncology studies, such as myeloma and lymphoma trials.
Keep up to date with health board news by signing up to our mailing list Sign up (es-mail.co.uk)